Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Vollmer

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
International Journal of MS Care|January 17, 2022
NARCOMS and Other Registries in Multiple Sclerosis: Issues and InsightsRuth Ann Marrie, Gary R Cutter, Robert J Fox, et al.
Disability and Health Journal|December 3, 2010
A pilot study of young adults with multiple sclerosis: demographic, disease, treatment, and psychosocial characteristicsRobert J Buchanan, Sarah L Minden, Bonnie J Chakravorty, et al.
Annals of Clinical and Translational Neurology|March 9, 2019
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatmentBrandi L Vollmer, Kavita V Nair, Stefan Sillau, et al.
Journal of the Neurological Sciences|May 27, 2018
The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosisBrandi Vollmer, Justin M Honce, Stefan Sillau, et al.
International Journal of MS Care|June 3, 2016
Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple SclerosisJonathan Calkwood, Timothy Vollmer, Robert J Fox, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Cognitive reserve and appraisal in multiple sclerosisCarolyn E Schwartz, Erin Snook, Brian Quaranto, et al.
Multiple Sclerosis and Related Disorders|January 21, 2017
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosisYing Liu, Timothy Vollmer, Eva Havrdova, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 16, 2013
Fluctuations in appraisal over time in the context of stable versus non-stable healthCarolyn E Schwartz, Brian R Quaranto, Bruce D Rapkin, et al.
Patient Preference and Adherence|July 4, 2017
Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosisJohn F Foley, Kavita V Nair, Timothy Vollmer, et al.
Current Medical Research and Opinion|May 22, 2016
Determinants of high cost in multiple sclerosis patients: a claims and chart review studyXuehua Ke, Prakash Navaratnam, Rahul Sasane, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
International Journal of MS Care|January 17, 2022
NARCOMS and Other Registries in Multiple Sclerosis: Issues and InsightsRuth Ann Marrie, Gary R Cutter, Robert J Fox, et al.
Disability and Health Journal|December 3, 2010
A pilot study of young adults with multiple sclerosis: demographic, disease, treatment, and psychosocial characteristicsRobert J Buchanan, Sarah L Minden, Bonnie J Chakravorty, et al.
Annals of Clinical and Translational Neurology|March 9, 2019
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatmentBrandi L Vollmer, Kavita V Nair, Stefan Sillau, et al.
Journal of the Neurological Sciences|May 27, 2018
The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosisBrandi Vollmer, Justin M Honce, Stefan Sillau, et al.
International Journal of MS Care|June 3, 2016
Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple SclerosisJonathan Calkwood, Timothy Vollmer, Robert J Fox, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Cognitive reserve and appraisal in multiple sclerosisCarolyn E Schwartz, Erin Snook, Brian Quaranto, et al.
Multiple Sclerosis and Related Disorders|January 21, 2017
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosisYing Liu, Timothy Vollmer, Eva Havrdova, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 16, 2013
Fluctuations in appraisal over time in the context of stable versus non-stable healthCarolyn E Schwartz, Brian R Quaranto, Bruce D Rapkin, et al.
Patient Preference and Adherence|July 4, 2017
Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosisJohn F Foley, Kavita V Nair, Timothy Vollmer, et al.
Current Medical Research and Opinion|May 22, 2016
Determinants of high cost in multiple sclerosis patients: a claims and chart review studyXuehua Ke, Prakash Navaratnam, Rahul Sasane, et al.
Pageof 8